Emerging frontiers in adoptive cell therapies: engineering innovations, current challenges, and manufacturing perspectives.

Authors

Mahdieh Sadat Hosseini Nezhad, Sarvenaz Zeighami Gol, Pouya Gharavi, Hossein Javid

Published in

Molecular biology reports. Volume 53. Issue 1. Sep 08, 2026. Epub Sep 08, 2026.

Abstract

Immunotherapy through adoptive cell therapy (ACT) has become an effective cancer treatment method, using genetically modified immune cells or immune cells grown outside the body. The ACT methods use chimeric antigen receptor T (CAR-T) cells, with proven results for blood cancers, while tumor-infiltrating lymphocytes (TILs) and T-cell receptor (TCR)-engineered T cells serve as effective methods to fight against solid tumors and intracellular antigens. The current medical field uses natural killer (NK) cell-based therapies because of their natural ability to destroy cells, their lower incidence of graft-versus-host disease, and their capability to generate readily available therapeutic products through allogeneic medical procedures. The clinical utilization of ACTs has been facing multiple obstacles, stemming from antigen diversity, immune system resistance, treatment-related adverse effects, and difficulties in production. The researchers are advancing multiple solutions to resolve current challenges through developing multi-targeted receptor designs and gene-editing technologies, enhanced cell persistence strategies, and scalable manufacturing platforms. The next-generation ACT platforms will achieve improved therapeutic results through a mix of combination therapies, biomarker-driven patient selection, and advanced manufacturing technologies. Emerging areas of biological research demonstrate how adoptive cell therapies can develop into key components of precision cancer immunotherapy. In this review, we discussed the principles, benefits, and challenges of ACT, with a focus on potential solutions to overcome these obstacles.

PMID:
42709257
Bibliographic data and abstract were imported from PubMed on 09 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.